Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Vandetanib (Primary)
- Indications Head and neck cancer; Precancerous conditions
- Focus Biomarker; Therapeutic Use
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 02 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.